The latest Oncology News from reliable sources can be found on the MediPaper website. Get an instant update with the latest developments in Oncology.

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

This year’s American Society of Clinical Oncology (ASCO) annual meeting includes two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.

Interest Builds in CSF1R for Targeting Tumor Microenvironment

A growing appreciation of the role of the tumor microenvironment in fostering the development of malignancies is prompting the pursuit of anticancer therapies that target components of this supportive niche as opposed to the tumor itself.

Read full article (External website)

A Look Back at FDA News in the Month of March

Several new indications were approved by the FDA in March, including blinatumomab (Blincyto) for MRD+ ALL, brentuximab vedotin (Adcetris) for Hodgkin lymphoma, and a 4-week nivolumab (Opdivo) dosing schedule across several indications. Here’s a look back on the FDA happenings for the month of March 2018.

Read full article (External website)

FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia

The FDA has granted a priority review to moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.

Read full article (External website)

Patient-Derived Organoids Can Recapitulate Patient Responses in the Clinic

Comparison of organoid drug responses with how the patients with metastatic gastrointestinal cancers responded in the clinic

Read full article (External website)

Olaparib Under Review by EMA for BRCA-mutated, HER2-negative Breast Cancer

A marketing authorization application for olaparib (Lynparza) for the treatment of women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting has been accepted by the European Medicines Agency.

Read full article (External website)

Larotrectinib Exceeds 90% Response Rate in TRK+ Pediatric Cancers

Larotrectinib induced an “unprecedented” objective response rate of 93% in patients with TRK fusion–positive solid tumors.

Read full article (External website)

EMA Recommends Extension of Therapeutic Indications for Denosumab

Change in indications considers prevention of skeletal related events in adults with advanced malignancies involving bone

Read full article (External website)

Kris on the Success of Durvalumab as a Major Advancement in NSCLC

In an interview with Targeted Oncology, Kris, a medical oncologist and the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, discussed how the approval of durvalumab has changed the treatment landscape of NSCLC.

Read full article (External website)

EMA to Review Olaparib in BRCA-mutated, HER2-negative Breast Cancer

The European Medicines Agency has accepted a marketing authorization application for olaparib to treat women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

Read full article (External website)

Increased Levels of Screening for Symptoms of Metabolic Syndrome Called for in Testicular Cancer Survivors

Investigators report for the first time clinical and genetic risk factors for metabolic syndrome in North American survivors of testicular cancer

Read full article (External website)

Denosumab Granted European Approval for Myeloma

Based on data from the Phase 3 482 trial, denosumab (Xgeva) has been approved for an expanded indication by the European Commission for the prevention of skeletal-related events in adult patients with multiple myeloma, according to Amgen, the developer of the RANK ligand inhibitor.

Read full article (External website)

Denosumab Approved in Europe for Myeloma

The European Commission has approved denosumab for the prevention of skeletal-related events in adult patients with multiple myeloma.

Read full article (External website)

Nivolumab Delivers Durable Response in Hodgkin Lymphoma at 18 Months

In an extended follow-up of results from the CheckMate-205 trial, nivolumab (Opdivo) induced an overall objective response rate of 69% in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation.

Read full article (External website)

Novel Radiolabeled ADC Could Improve Outcomes in High-Risk AML

Older patients with active, relapsed, or refractory acute myeloid leukemia have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy.

Read full article (External website)

HPV Vaccination Should Be Part of Oncology Cost-Reduction Strategy

The impact of staggering increases in the cost of individual antineoplastic agents for patients and the overall healthcare system cannot be overstated, and there appears to be no realistic solution to the current dilemma that is acceptable to the parties involved in this ongoing debate.

Read full article (External website)

Lynch

Thomas J. Lynch, Jr, MD, brings an enthusiasm to exploring and developing treatments to help patients with cancer.

Read full article (External website)

MRD Prognostic of Poorer Outcomes in AML

Molecular minimal residual disease was associated with a higher rate of relapse and a lower rate of relapse-free survival and overall survival for patients with newly-diagnosed acute myeloid leukemia.

Read full article (External website)

AKT Inhibitor May Overcome Chemotherapy Resistance in 2 Breast Cancer Subtypes

A novel inhibitor that targets the AKT node in the PI3K pathway may offer a treatment option in cases of resistance to chemotherapy in 2 patient populations: triple-negative breast cancer or estrogen receptor

Read full article (External website)

Expert Discusses Immunotherapy Advancements in a Rapidly Changing GU Field

Ani S. Balmanoukian, MD, discusses immunotherapy developments in GU malignancies

Read full article (External website)

Expert Discusses Next Steps After Dramatic Shift in Management of AML

Stuart L. Goldberg, MD, discussed the management of patients with acute myeloid leukemia as well as those with myelodysplastic syndrome.

Read full article (External website)

Ongoing Advances Transforming Treatment in Myeloma

Noa Biran, MD, discusses treatment breakthroughs and emerging advances in the field of multiple myeloma.

Read full article (External website)

Multimodal Approaches Emerging in Locally Advanced Prostate Cancer

Edouard J. Trabulsi, MD, discusses emerging multimodal treatment approaches for patients with locally advanced prostate cancer.

Read full article (External website)

AML Treatment Additions Encouraging, But MDS Landscape Still Facing Challenges

Stuart L. Goldberg, MD, discusses the management of patients with acute myeloid leukemia as well as those with myelodysplastic syndrome.

Read full article (External website)

Thomas Gallo Named 2018-2019 ACCC President

The Association of Community Cancer Centers (ACCC) has named Thomas A. Gallo, MS, MDA, as the 2018-2019 president of ACCC. This was announced at the ACCC’s 44th Annual Meeting & Cancer Center Business Summit on March 16, 2018.

Read full article (External website)

Pereira Offers View on the Importance of Maintenance Therapy for patients With Multiple...

Denise. L. Pereira, MD, recently shared the treatment considerations and decisions she makes when treating patients with multiple myeloma based on 2 case scenarios during a Targeted Oncology live case-based peer perspectives presentation.

Read full article (External website)

MURANO trial Results Demonstrate PFS Benefit with Venetoclax/Rituximab

According to findings from the Phase 3 MURANO trial recently published in the New England Journal of Medicine, the venetoclax (Venclexta) plus rituximab (Rituxan) regimen lowered the risk of disease progression or death by 83% in comparison with bendamustine (Treanda) plus rituximab (Rituxan) in patients with relapsed or refractory chronic lymphocytic leukemia.

Read full article (External website)

Death due to cancer on the decline for most tumours in Europe

The exceptions are death due to lung and pancreatic carcinoma in women which are both still on the rise, according to a new study, published in Annals of Oncology on the 19th of March 2018.

Researchers predict that the death rates for most types of cancer will be lower in 2018 when compared to 2012 in the European Union.

The study, led by Carlo La Vecchia (MD) of the University of Milan, shows that death due to colorectal cancer (CRC) is on the decline in Europe. The researchers call the drop in death-rates of CRC, which is the most common cause of cancer-death in non-smoking males and females, one of the major achievements in the management of oncologic diseases over the recent years.

Key numbers for CRC:

  • CRC is the second highest cause of cancer-death: 177,400 (male: 98,000 in men; female 79,400);
  • Due to the ageing population, the absolute quantities of fatalities have risen since 2012;
  • In contrast, the age-standardised rates will decrease by 6.7% in men (15.8 per 100,000) and 7.5% in women (9.2 per 100,000).

Risk factors for CRC include:

  • Tobacco
  • Alcohol
  • Obesity
  • Diabetes
  • Sedentary lifestyle
  • Unhealthy diet

The use of oral contraceptives and hormone-replacement therapy in women may partly explain the decreased risk in females. Furthermore, the use of aspirin for prevention of cardiovascular disease and effective screening may further contribute to a decrease in the incidence of the disease in both sexes.

Key numbers for all cancers in Europe:

  • In 2018, 1.4 million cancer deaths are predicted, up from 1.3 million in 2012.
  • Death-rates have fallen by 10.3% in men and 5% in women
  • Age-standardised death rates in 2018 are predicted to be 130 per 100,000 for men and 84 per 100,000 for women.

Citations

  1. Malvezzi M et al. Ann Oncol. doi:10.1093/annonc/mdy033

Bendell Takes the Helm as Chief Development Officer at Sarah Cannon

Internationally renowned expert, Johanna C. Bendell, MD, has been promoted to chief development officer at Sarah Cannon. Her title responsibilities include developing and expanding physician, site, and Pharma relationships across the Sarah Cannon Network, thereby expanding the organization’s efforts to bring more qualitative treatment options to its patients.

Read full article (External website)

Expert Discusses Potential Expansions to the Treatment Landscape in RCC

Treatment of renal cell carcinoma (RCC) is awaiting the potential integration of combinations of immuno-oncology agents like nivolumab (Opdivo) and ipilimumab (Yervoy), or combinations of targeted therapies with checkpoint inhibitors into the treatment paradigm. In an interview with Targeted Oncology, Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Read full article (External website)

EBRT Effective in Relapsed/Refractory Follicular Lymphoma

Findings from a small, retrospective trial delivered that external beam radiation therapy induced an overall response rate of 86% in patients with relapsed/refractory follicular lymphoma.

Read full article (External website)

Expert Highlights Current Advancements and Questions in Breast Cancer Treatment

Kornelia Polyak, MD, PhD, discusses several exciting advancements in the field of breast cancer, including immunotherapy, PARP inhibitors, and liquid biopsies.

Read full article (External website)

Precision Medicine Impact Grows in GI Cancer Paradigm

Bert H. O’Neil, MD, the role of molecular testing throughout GI cancers and highlighted the current and developing treatment landscape for patients with colorectal cancer.

Read full article (External website)

Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.

Read full article (External website)

Blinatumomab Granted FDA Approval for MRD+ ALL

Blinatumomab (Blincyto) has been granted an accelerated approval by the FDA for the treatment of patients with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.

Read full article (External website)

Bekaii-Saab Highlights Emerging Agents in Pancreatic Cancer Pipeline

Tanios Bekaii-Saab, MD, discusses emerging treatments offering hope to patients with pancreatic cancer.

Read full article (External website)

Expert Discusses Promise of Novel Sarcoma Vaccine and Other Ongoing Research in the Field

In an interview with Targeted Oncology, Pollack, assistant member, Clinical Research Division, assistant professor, Division of Oncology, University of Washington, and attending physician at Seattle Cancer Care Alliance, discussed some of the advancements his lab is making in the field of sarcoma.

Read full article (External website)

Trastuzumab Regimen Extends PFS in Rare Endometrial Cancer

Adding trastuzumab to chemotherapy increased progression-free survival for patients with advanced HER2/neu-positive uterine serous carcinoma,

Read full article (External website)

Nilotinib Granted FDA Approval for Pediatric CML

Based on data from 2 clinical trials, nilotinib (Tasigna) has been approved by the FDA for the first- and 2nd-line treatment of pediatric patients aged 1 year and older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase.

Read full article (External website)

Immunotherapy Arrives in Gastric Cancer

Manish A. Shah, MD, discusses the advancements being made in the treatment of patients with advanced gastric and gastroesophageal junction cancer.

Read full article (External website)

EMA Recommends Extension of Therapeutic Indications for Fosaprepitant

It is indicated for prevention of nausea and vomiting associated with highly and moderately emetogenic chemotherapy in adult and paediatric patients

Read full article (External website)

New Drug Application Completed for Larotrectinib for Solid Tumors Harboring NTRK Gene...

The new drug application (NDA) for larotrectinib (LOXO-101) for treatment of patients with locally advanced or metastatic solid tumors that habor an NTRK gene fusion has been completed.

Read full article (External website)

FDA Grants Accelerated Approval to Blinatumomab for the Treatment of B-cell Precursor ALL

It is indicated in adult and paediatric patients in first or second complete remission with minimal residual disease

Read full article (External website)

Priority Review Granted by FDA for Nivolumab Plus Ipilimumab Combo for MSI-H/dMMR CRC

There has been a supplemental biologics license application (sBLA) granted priority review by the FDA for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cases of metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Read full article (External website)

Cheson Considers the Most Effective Therapeutic Strategies for patients With Follicular...

Bruce D. Cheson, MD, recently shared the treatment options and decisions he makes when treating patients with follicular lymphoma based on 2 case scenarios during a Targeted Oncology live case-based peer perspective presentation.

Read full article (External website)

Expert Discusses Bone-Targeting Agents in Prostate Cancer

Robert B. Den, MD, discusses bone-targeting agents in prostate cancer and the potential future of combinations.

Read full article (External website)

Depression Treatment Does Not Improve the Survival of Depressed patients with Cancer

Management of depression remains important for its beneficial effect on QoL in cancer patients

Read full article (External website)

Combination of Atezolizumab and Cobimetinib Active in mCRC

The combinations of atezolizumab and cobimetinib induced a 31% disease control rate in patients with heavily-pretreated metastatic colorectal cancer. Results from a 2-stage phase Ib trial presented at the 2018 Gastrointestinal Cancers Symposium demonstrated an overall response rate of 8% (n = 7). All responses were partial responses.

Read full article (External website)

Surgical Techniques Continue to Evolve in NSCLC

Jason M. Long, MD, discusses the latest developments with minimally invasive surgical approaches in the treatment of patients with non–small cell lung cancer (NSCLC).

Read full article (External website)

Asian AYA Cancer Care Survey

This survey is organised by the ESMO/SIOPE Cancer in Adolescent and Young Adults (AYA) Working Group following successful mapping of the European AYA cancer care landscape.

Read full article (External website)

Enzalutamide Granted FDA

Based on data from the Phase 3 PROSPER trial, a supplemental new drug application for enzalutamide for the treatment of men with nonmetastatic castration-resistant prostate cancer has been granted a priority review by the FDA, according to Pfizer and Astellas, the companies developing the antiandrogen agent.

Read full article (External website)

Prostate Cancer Screening and Surveillance Continue to Evolve

William K. Kelly, DO, discusses the evolving imaging techniques and emerging therapeutic approaches in prostate cancer.

Read full article (External website)

Metastatic Prostate Cancer Project Explores a New Approach to Genomics Research

The project aims to improve understanding of prostate cancer genomics through direct-to-patient approach

Read full article (External website)

CMS Announces Decision to Cover Genomic Testing for patients With Cancer

In a national coverage determination issued March 16, CMS announced that it will cover diagnostic laboratory tests using next-generation sequencing for patients with advanced cancer.

Read full article (External website)

Weiss Weighs In on Challenges in NSCLC

Jared Weiss, MD, shares his insight on challenges in the field of non–small cell lung cancer, such as optimal sequencing.

Read full article (External website)

ELCC 2018 Media Alert: Fighting Number-one Cancer Killer With Research and A Multidisciplinary Approach

Around 2,300 participants from across the world will meet in Geneva at the eighth European Lung Cancer Congress (ELCC 2018, 11-14 April 2018) to learn about and discuss the latest research in the field of lung cancer.

Read full article (External website)

Trastuzumab Biosimilar Receives Positive Opinion From CHMP for European Approval

A marketing authorization for ABP 980, a biosimilar to trastuzumab (Herceptin), has been issued a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Read full article (External website)

FDA Approves Blinatumomab for MRD+ ALL

The FDA has approved blinatumomab for the treatment of patients with minimal residual disease–positive B-cell precursor acute lymphoblastic leukemia.

Read full article (External website)

Social Network Index Developed to Assess the Support Resources of Adolescent and Young Adult Cancer Survivors

A functional social network index was developed that is specific for adolescent and young adult survivors of cancer

Read full article (External website)

T-VEC Injections Safe in patients with Advanced-Stage Liver Metastases

According to early results of an ongoing early-phase trial presented at the 2018 Society of Interventional Radiology Annual Scientific Meeting, image-guided injections of talimogene laherparepvec immunotherapy (T-VEC, Imylgic) were deemed tolerable in patients with advanced-stage liver metastases.

Read full article (External website)

Expert Sheds Light on Recent Advances in mCRC

Shubham Pant, MD, shares his insight on the future direction of the treatment landscape of colorectal cancer.

Read full article (External website)

ESMO Asia 2018: Abstracts

Abstract submission for ESMO Asia 2018 is open. Submit your abstract now!

Read full article (External website)

EMA Suggests Extension of Therapeutic Indications for Denosumab

Extension of indication includes the avoidance of skeletal-related events in grown-ups with late-stage malignancies involving the bone

On 22 February 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending towards a change in the marketing authorisation for denosumab (licensee: Amgen Europe BV).

The following extension of the label was adopted by the CHMP:

  • Prevention of skeletal-related events in adults with advanced malignancies involving bone (e.g. pathological fracture, radiation to the bone, spinal cord compression, or surgery to the bone).

Previously, denosumab was only indicated for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

Reference:
http://www.esmo.org/Oncology-Information/EMA-Endorses-Extension-of-Therapeutic-Indications-for-Denosumab2

Promise Seen With Frontline Pembrolizumab Plus Chemotherapy in Ovarian Cancer

The combination of first-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab (Keytruda), followed by pembrolizumab maintenance therapy, was safe and tolerable in patients with advanced ovarian cancer, according to preliminary data from a small clinical trial presented at the 2018 Society of Gynecologic Oncology Annual Meeting.

Read entire post (External website)

Larotrectinib FDA Submission Completed for TRK Fusion Cancer

A rolling new drug application has been completed for larotrectinib (LOXO-101) for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion.

Read full article (External website)

Insufficient Evidence of Clinical Validity and Utility for the Majority of ctDNA Assays in Advanced Cancer

Robust research is needed in several areas to enable development of clinical practice recommendations

Read full article (External website)

How Can We Do Better at Preventing Cancer?


English
February 22, 2018
lidia.schapira

In this month’s From the Editor’s Desk, Dr. Schapira writes about prevention and what we can do to help understand and manage our personal cancer risk.

Read full article (External website)

Expert Discusses Immunotherapy Growth in Treatment Landscape of NSCLC

The treatment landscape of non-small cell lung cancer has been identifying the importance of immunotherapy already, but combination therapies will soon play a large role in treatment of these patients as well, according to Chad Pecot, MD.

Read full article (External website)

Biosimilar Filgrastim Safety Confirmed in Analysis

EP2006, a filgrastim biosimilar, produced safety results equivalent to those observed with referent filgrastim in a combined analysis of 2 Phase 3 breast cancer studies from the United States and Europe.

Read full article (External website)

Immune-Modified Response Criteria in Solid Tumours

Analyzis of atezolizumab data in clinical trials including NSCLC, mUC, RCC and melanoma patients may inform additional modifications to response evaluation criteria

Read full article (External website)

Managing Eating Challenges After Head and Neck Cancer Treatment


English
February 28, 2018
gregguthrie

In this podcast, registered dietitians Annette Goldberg and Maureen Gardner discuss ways to cope with side effects that can make eating difficult due to treatment for head and neck cancer.

Read full article (External website)

trial Finds Survival Benefit With Upfront Atezolizumab Combo for NSCLC

According to findings from the Phase 3 IMpower150 trial, significant improvement was found in overall survival with a treatment regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel compared to the combination of bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.

Read full article (External website)

FDA Grants Nivolumab/Ipilimumab Priority Review for MSI-H/dMMR Colorectal Cancer

The FDA has granted a priority review to a supplemental biologics license application for nivolumab plus ipilimumab for the treatment of adult patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Read full article (External website)

Substantial Genomic Heterogeneity Characterises TNBC Molecular Subtypes

An integrative multiomic analysis identifies several candidate targets

Read full article (External website)

What Are Liquid Biopsies and How Are They Used?


English
March 5, 2018
Monika.Sharda

In this podcast, Professor Nick Turner, MD, talks about a joint review from ASCO and CAP that provides guidance on using liquid biopsies.

Read full article (External website)

Enfortumab Vedotin Granted FDA

Enfortumab vedotin has been granted a breakthrough therapy designation by the FDA for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint therapy. These findings have been released by Seattle Genetics and Astellas, the manufacturers of the antibody-drug conjugate.

Read full article (External website)

Trastuzumab Deruxtecan Receives Expedited Review in Japan for Gastric Cancer

Japanese regulators have granted a Sakigake designation to trastuzumab deruxtecan (DS-8201), for the treatment of patients with HER2-positive gastric cancer that is refractory to trastuzumab (Herceptin).

Source

ESMO Symposium on Signalling Pathways in Cancer 2018: Meeting Resources

Webcasts and presentations from can be accessed by ESMO members and event attendees

Source

“Your Stories” Podcasts: How Cancer Impacts Families


English
March 8, 2018
PATRA.WROTEN

The Your Stories podcast series from ASCO’s Conquer Cancer Foundation provides insight into what it’s like to conquer cancer from different viewpoints. The podcasts featured here touch on the many ways that cancer can affect a family.

Source

TTFields with Temozolomide Recommended by NCCN for Newly Diagnosed GBM

The combination of TTFields and temozolomide has been added by the NCCN to its guidelines for Category 1 treatment for patients with newly diagnosed glioblastoma, following maximal safe resection and completion of radiation therapy.

Source

Frontline Pembrolizumab Plus Chemo Shows Promise in Ovarian Cancer

1st-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.

Source

FDA Approves Brentuximab Vedotin for Previously Untreated Stage III or IV Classical Hodgkin Lymphoma

Approval is based on results from the ECHELON-1 trial

Source

What You Need to Know About Colorectal Cancer

2018-03-13 21:00:00


English
March 13, 2018
Jeffrey.Meyerhardt

Being diagnosed with colorectal cancer can be scary and confusing. Dr. Jeffrey Meyerhardt, an expert in colorectal cancer, describes the 4 questions that any newly diagnosed patient should ask.

Source

Earlier Pseudoprogression Seen in Patients With Oligodendroglioma Treated With Proton...

Earlier Pseudoprogression Seen in patients With Oligodendroglioma Treated With Proton...

2018-03-29 11:07:11

patients with oligodendroglioma developed pseudoprogression earlier after treatment with proton therapy compared with after photon therapy, according to the results of a retrospective trial comparing the rates of pseudoprogression that occurred in patients with anaplastic gliomas following treatment with different radiation therapy modalities.

Source

Genetic Testing Helps Guide Treatment in Prostate Cancer

Genetic Testing Helps Guide Treatment in Prostate Cancer

2018-03-28 22:15:00

Veda Giri, MD, discusses the developing role of genetic testing for the screening and management and of patients with prostate cancer.

Source

Oncology Breast CNS Chemotherapy Endocrine GI GU Geriatric Gynecologic GYN-OB Head and Neck Haematology Immunotherapy Lung Melanoma Skin NET Paediatric Pathology Sarcoma Surgery Targeted Therapy Translational

EMA Recommends Granting a Conditional Marketing Authorisation for Rucaparib

2018-03-27 03:31:00

It is recommended in previously treated platinum-sensitive, relapsed or progressive BRCA mutated high-grade epithelial ovarian cancer

Source

From Inspired to Involved: Why I Became a Breast Cancer Advocate

From Inspired to Involved: Why I Became a Breast Cancer Advocate

2018-03-15 22:00:00


English
TeMaya Eatmon, Voices on Cancer
March 15, 2018
TeMaya.Eatmon

TeMaya Eatmon’s friendship with a fellow breast cancer patient inspired her in ways she never imagined possible. Learn how heartbreaking loss led to a life-changing role as an advocate.

Source

PFS Improved in Frontline Squamous NSCLC with Atezolizumab Plus Chemo

PFS Improved in Frontline Squamous NSCLC with Atezolizumab Plus Chemo

2018-03-29 10:54:57

According to topline findings from the Phase 3 IMpower131 trial, the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer. These results were released by Genentech, the manufacturer of the anti–PD-L1 agent.

Source

Expert Discusses Optimizing CDK 4/6 Inhibitors in Breast Cancer

Expert Discusses Optimizing CDK 4/6 Inhibitors in Breast Cancer

2018-03-29 00:19:00

Reshma Mahtani, DO, discusses the tolerability of CDK 4/6 inhibitors for the treatment of patients with metastatic breast cancer.

Source

ELCC 2018 Press Release: Heine H. Hansen Award Given to Fabrice Barlesi

2018-03-27 06:05:00

The European Society for Medical Oncology (ESMO) and the International Association for the trial of Lung Cancer (IASLC) have announced that the 2018 Heine H. Hansen (HHH) Award will be given to Fabrice Barlesi.

Source

Brentuximab Vedotin Approved by FDA for Hodgkin Lymphoma

Brentuximab Vedotin Approved by FDA for Hodgkin Lymphoma

2018-03-29 10:42:10

Based on findings from the Phase 3 ECHELON-1 trial, brentuximab vedotin (Adcetris) has been approved by the FDA for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma, according to a statement from Seattle Genetics, the manufacturer of the CD30-targeted antibody-drug conjugate.

Source

Durvalumab Success Signifies New Era in Stage III NSCLC

Durvalumab Success Signifies New Era in Stage III NSCLC

2018-03-29 02:00:00

Edward S. Kim, MD, recaps the findings from the PACIFIC trial of durvalumab and discussed the treatment of patients with stage III NSCLC.

Source

EMA Recommends Extensions of Indications for Cabozantinib

2018-03-27 12:41:00

New indication concerns treatment-naive adults with intermediate or poor risk advanced RCC

Source

Cancer Stories: How We Make Sense of Cancer

Cancer Stories: How We Make Sense of Cancer

2018-03-22 21:00:00


English
From the Editor's Desk
March 22, 2018
lidia.schapira

In this month’s From the Editor’s Desk, Dr. Schapira writes about the power of storytelling in cancer care and how this led to the development of a podcast series with the Journal of Clinical Oncology.

Source

Oncology Breast CNS Chemotherapy Endocrine GI GU Geriatric Gynecologic GYN-OB Head and Neck Haematology Immunotherapy Lung Melanoma Skin NET Paediatric Pathology Sarcoma Surgery Targeted Therapy Translational

Durable Responses to JCAR017 Observed in High-Risk DLBCL

2018-03-29 10:30:12

Responses to lisocabtagene maraleucel have been potent and durable in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma. Separate exploratory analyses of this population treated with liso-cel found that high tumor burden and a series of in ammatory biomarkers were associated with high chimeric antigen receptor T-cell expansion and higher rates of cytokine release syndrome and neurotoxicity.

Source

Challenges Continue With Lung Cancer Screening

Challenges Continue With Lung Cancer Screening

2018-03-29 02:42:00

M. Patricia Rivera, MD, discusses the potential of lung cancer screening, challenges in its adoption, and methods to enhance its efficacy.

Source

FDA Approves Nilotinib for Paediatric patients with Newly Diagnosed or Resistant/Intolerant Ph-Positive CML in Chronic Phase

2018-03-28 22:16:00

Approval is based on results in paediatric patients from CAMN107A2120 and CAMN107A2203 studies

Source

Mammograms and Older Women: Is It Ever Safe to Stop?

Mammograms and Older Women: Is It Ever Safe to Stop?

2018-03-27 21:00:00


English
March 27, 2018
Rachel.Freedman

Mammograms are a very important part of follow-up care in women with breast cancer. But what about older women? How long should they continue to receive mammograms?

Source

Trials Consider Role of Immunotherapy in Breast Cancer

Trials Consider Role of Immunotherapy in Breast Cancer

2018-03-29 10:16:32

Mixed results have occured in recent trials testing immuotherapy in patients with breast cancer. Checkpoint inhibitors have been used as monotherapy in a pair of trials, reporting lackluster overall response rates. When immunotherapy was paired with chemotherapy, on the other hand, it usually revealed better results, and gave signals that immunotherapies combined with targeted agents could work better than immunotherapy alone.

Source